- Home
- BDTX vs NKTX Comparison
BDTX vs NKTX Comparison
Compare BDTX & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | NKTX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.1M | 132.8M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BDTX | NKTX |
|---|---|---|
| Price | $2.48 | $2.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $10.40 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 903.9K | 891.9K |
| Earning Date | 03-05-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $70,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.20 | $1.31 |
| 52 Week High | $4.94 | $2.74 |
Technical Indicators
Market Signals| Indicator | BDTX | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.70 | 52.62 |
| Support Level | $2.49 | $2.40 |
| Resistance Level | $2.70 | $2.56 |
| Average True Range (ATR) | 0.15 | 0.14 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 24.47 | 41.04 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.